Cargando…

Changes in musculoskeletal disease activity and patient-reported outcomes in patients with psoriatic arthritis treated with ixekizumab: results from a real-world US cohort

INTRODUCTION: Ixekizumab has demonstrated efficacy in pivotal trials in patients with psoriatic arthritis (PsA), both those naïve to prior biologic therapy and those with prior inadequate response or intolerance to biologics; however, minimal information is currently available on the effectiveness o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tillett, William, Birt, Julie, Cavanaugh, Cristi, Jung, Yoojin, Vadhariya, Aisha, Ross, Sarah, Paulus, Jessica, Lubrano, Ennio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322216/ https://www.ncbi.nlm.nih.gov/pubmed/37415769 http://dx.doi.org/10.3389/fmed.2023.1184028

Ejemplares similares

Ixekizumab for Psoriatic Arthritis: Safety, Efficacy, and Patient Selection
por: Miller, John, et al.
Publicado: (2021)

Real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications among patients with psoriatic arthritis treated with IL-17A inhibitors in the United States
por: Pizzicato, Lia N, et al.
Publicado: (2023)

Persistence and Use of Ixekizumab in Patients with Psoriatic Arthritis in Real-World Practice in Spain. The PRO-STIP Study
por: Joven, Beatriz, et al.
Publicado: (2023)

Real‐World Treatment Patterns and Healthcare Costs in Patients with Psoriatic Arthritis Treated with Ixekizumab: A Retrospective Study
por: Murage, Mwangi J., et al.
Publicado: (2021)

Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis
por: Gladman, Dafna D., et al.
Publicado: (2019)

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)
por: Gottlieb, Alice B, et al.
Publicado: (2018)

Secukinumab for ankylosing spondylitis and psoriatic arthritis
por: Lubrano, Ennio, et al.
Publicado: (2016)

Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2)
por: Orbai, Ana-Maria, et al.
Publicado: (2020)

Difficult to Treat and Refractory to Treatment in Psoriatic Arthritis
por: Lubrano, Ennio, et al.
Publicado: (2023)

Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials
por: Mease, Philip, et al.
Publicado: (2019)

Real-world burden of comorbidities in US patients with psoriatic arthritis
por: Shah, Kamal, et al.
Publicado: (2017)

The “Climb” Towards Minimal Disease Activity in Psoriatic Arthritis
por: Lubrano, Ennio, et al.
Publicado: (2021)

Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)
por: Chandran, Vinod, et al.
Publicado: (2020)

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
por: Lubrano, Ennio, et al.
Publicado: (2019)

Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain
por: Schweikert, Bernd, et al.
Publicado: (2020)

Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure
por: Deodhar, Atul A, et al.
Publicado: (2022)

Corticosteroid injection treatment for dactylitis in psoriatic arthritis
por: Carriero, Antonio, et al.
Publicado: (2021)

Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis
por: Montepaone, Monica, et al.
Publicado: (2014)

Treatment Retention and Safety of Ixekizumab in Psoriatic Arthritis: A Real Life Single-Center Experience
por: Braña, Ignacio, et al.
Publicado: (2023)

A Threshold of Meaning for Work Disability Improvement in Psoriatic Arthritis Measured by the Work Productivity and Activity Impairment Questionnaire
por: Tillett, William, et al.
Publicado: (2019)

Using Bayesian networks to identify musculoskeletal symptoms influencing the risk of developing psoriatic arthritis in people with psoriasis
por: Green, Amelia, et al.
Publicado: (2021)

Pharmacoeconomic burden in the treatment of psoriatic arthritis: from systematic reviews to real clinical practice studies
por: Lubrano, Ennio, et al.
Publicado: (2014)

Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials
por: Genovese, Mark C, et al.
Publicado: (2020)

Treatment with Ixekizumab Following Secukinumab Failure in Patients with Psoriatic Arthritis: Real-Life Experience from a Resistant Population
por: Berman, Julia, et al.
Publicado: (2021)

Adalimumab Biosimilar-Induced Severe Paradoxical Palmoplantar Pustulosis in a Patient with Psoriasis and Psoriatic Arthritis Successfully Treated with Ixekizumab
por: Gkalpakiotis, Spyridon, et al.
Publicado: (2022)

Responses to Ixekizumab in Male and Female Patients with Psoriatic Arthritis: Results from Two Randomized, Phase 3 Clinical Trials
por: Eder, Lihi, et al.
Publicado: (2022)

Ultrasonographic Evaluation of Entheseal Fibrocartilage in Patients with Psoriatic Arthritis, Athletes and Healthy Controls: A Comparison Study
por: Perrotta, Fabio Massimo, et al.
Publicado: (2023)

Psoriatic Arthritis in Males and Females: Differences and Similarities
por: Lubrano, Ennio, et al.
Publicado: (2023)

Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
por: Elewski, Boni E., et al.
Publicado: (2022)

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
por: Coates, Laura C, et al.
Publicado: (2022)

Clinical Characteristics of Potential “Difficult-to-treat” Patients with Psoriatic Arthritis: A Retrospective Analysis of a Longitudinal Cohort
por: Perrotta, Fabio Massimo, et al.
Publicado: (2022)

Simple clinical indicators for early psoriatic arthritis detection
por: Caso, Francesco, et al.
Publicado: (2014)

Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis
por: Combe, Bernard, et al.
Publicado: (2020)

Corrigendum to: Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials
por: Genovese, Mark C, et al.
Publicado: (2021)

Improvement from ixekizumab treatment in patients with psoriatic arthritis who have had an inadequate response to one or two TNF inhibitors
por: Kirkham, Bruce, et al.
Publicado: (2021)

A case of esophageal candidiasis in a psoriatic patient treated with ixekizumab: Should treatment be discontinued?
por: Ruggiero, Angelo, et al.
Publicado: (2022)

New Insights in Physical Therapy and Rehabilitation in Psoriatic Arthritis: A Review
por: Perrotta, Fabio Massimo, et al.
Publicado: (2021)

Regular Exercise Improved Fatigue and Musculoskeletal Pain in Young Adult Psoriatic Patients without Psoriatic Arthritis
por: Diaz, Antonio J., et al.
Publicado: (2023)

A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
por: Kirkham, Bruce W., et al.
Publicado: (2023)

Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double‐Blind Withdrawal Study
por: Coates, Laura C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dqbse0iqssm1d5112b6hh343d8